ArticleJournal of immunology (Baltimore, Md. : 1950)2015
Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.
Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 68 citations in OpenAlex.
- Improved Systemic Immunochemotherapy Employing an Oxaliplatin-TLR7/8 Agonist Prodrug Strategy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) and Small Intestinal Submucosa (SIS) Hydrogel Composite Can Meliorate TNBS-Induced Experimental Colitis Through Regulating Inhibiting Macrophage Polarization Toward the M1 Phenotype.Mediators of inflammation · 2026Article
- IL-21 attenuates liver inflammation by enhancing myeloid-derived suppressor cells immunosuppressive function in chronic HBV infection.Journal of translational medicine · 2025Article
- Article
- Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.Molecular cancer · 2025Review
- DSP-0509, a TLR7 agonist, exerted synergistic anti-tumor immunity combined with various immune therapies through modulating diverse immune cells in cancer microenvironment.Frontiers in oncology · 2024Article
- MDSCs use a complex molecular network to suppress T-cell immunity in a pulmonary model of fungal infection.Frontiers in cellular and infection microbiology · 2024Article
- Toll-Like Receptors and the Response to Radiotherapy in Solid Tumors: Challenges and Opportunities.Vaccines · 2023Review
- "Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer.Frontiers in immunology · 2023Review
- MyD88-dependent Toll-like receptor 2 signaling modulates macrophage activation on lysate-adsorbed Teflon™ AF surfaces in anFrontiers in immunology · 2023Article
- Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy.Cancer cell international · 2022Review
- Identification of Biomarkers Related to M2 Macrophage Infiltration in Alzheimer's Disease.Cells · 2022Article
- Circulating biomarkers of inflammaging as potential predictors of COVID-19 severe outcomes.Mechanisms of ageing and development · 2022Review
- The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.Experientia supplementum (2012) · 2022Article
- Understanding the role of Toll-like receptors in lung cancer immunity and immunotherapy.Frontiers in immunology · 2022Review
- Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy.Frontiers in oncology · 2022Review
- Qingchang Wenzhong Decoction Alleviates DSS-Induced Inflammatory Bowel Disease by Inhibiting M1 Macrophage PolarizationBioMed research international · 2022Article
- Neutrophil-suppressive activity over T-cell proliferation and fungal clearance in a murine model of Fonsecaea pedrosoi infection.Scientific reports · 2021Article
- Granulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid Leukemia.Annals of laboratory medicine · 2021Article
- Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity.The Journal of clinical investigation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Tumors persist by occupying immunosuppressive microenvironments that inhibit the activity of tumoricidal T and NK cells. Monocytic myeloid-derived suppressor cells (mMDSC) are an important component of this immunosuppressive milieu. We find that the suppressive activity of mMDSC isolated from cancer patients can be reversed by treatment with TLR7/8 agonists, which induce human mMDSC to differentiate into tumoricidal M1-like macrophages. In contrast, agonists targeting TLR1/2 cause mMDSC to mature into immunosuppressive M2-like macrophages. These two populations of macrophage are phenotypically and functionally discrete and differ in gene expression profile. The ability of TLR7/8 agonists to reverse mMDSC-mediated immune suppression suggests that they might be useful adjuncts for tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.